An Ab­b­Vie clin­i­cal vet head­ing ear­ly on­col­o­gy jumps ship to build his own team at NK cell-fo­cused biotech

Mak­ing the leap from a mid-sized biotech in­to the ranks of phar­ma can be a chaf­ing ex­pe­ri­ence for ex­ec­u­tives used to a more flex­i­ble work en­vi­ron­ment — and that jump gets even hard­er dur­ing an ac­qui­si­tion. For Thorsten Graef, a clin­i­cal vet­er­an who tran­si­tioned from Phar­ma­cyclics in­to Ab­b­Vie, the move was a learn­ing ex­pe­ri­ence in terms of what sort of team he want­ed to run.

Now, he’s get­ting his chance.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN